AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7906536 — intervention group
Group type: EXPERIMENTAL
Intervention: British male average weight
Number of subjects: 80
Study 7906536 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian male average weight
Number of subjects: 80
Study 7906536 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 80
Study 2566338 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. manufactured 50 mg film coated, waxed tablets
Number of subjects: 34
Study 2566338 — intervention group
Group type: COMPARATOR
Intervention: European 50 mg film coated, waxed tablets
Number of subjects: 34
Study 2566338 — intervention group
Group type: COMPARATOR
Intervention: Oral reference solution of almitrine bismesylate (0.5% w/v)
Number of subjects: 34
Study 2566338 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. manufactured tablets vs. European tablets
Number of subjects: 34
Study 5060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 2
Study 5060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 600 mg
Number of subjects: 2
Study 5060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and Isoniazid combination
Number of subjects: 2
Study 5060669 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2
Study 30601823 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) with a clinic invitation letter
Number of subjects: 2349
Study 30601823 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST + $3 financial incentive
Number of subjects: 2349
Study 30601823 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST + $10 financial incentive
Number of subjects: 2349
Study 30601823 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST alone
Number of subjects: 2349
Study 30601823 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST + lottery (10% chance of $30)
Number of subjects: 2349
Study 30601823 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST + phone reminder
Number of subjects: 2349
Study 29320996 — intervention group
Group type: EXPERIMENTAL
Intervention: CCHP + HAP
Number of subjects: 945
Study 29320996 — intervention group
Group type: COMPARATOR
Intervention: CCHP + HAP Delayed
Number of subjects: 945
Study 25407258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg once daily for 8 days
Number of subjects: 21
Study 25407258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23070022 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu extract (250 mg isoflavones, t.i.d.)
Number of subjects: 17
Study 23070022 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 17
Study 22150036 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus VLP vaccine
Number of subjects: 98
Study 22150036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 19961457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 60
Study 19961457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation of ProTaper Gutta‐percha
Number of subjects: 60
Study 19961457 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ProTaper Gutta‐percha
Number of subjects: 60
Study 19961457 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm vertical condensation
Number of subjects: 60
Study 16314870 — intervention group
Group type: COMPARATOR
Intervention: PICK1 gene association study
Number of subjects: 0
Study 16314870 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine involvement
Number of subjects: 0
Study 15212772 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions including individually tailored newsletters, interpersonal activities, and community-wide events such as walk-a-thons.
Number of subjects: 12
Study 15212772 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions
Number of subjects: 12
Study 10867093 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 407
Study 10867093 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 407
Study 9351754 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bupivacaine
Number of subjects: 105
Study 9351754 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ketorolac
Number of subjects: 105
Study 9351754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8471652 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.6% BCAA solution
Number of subjects: 35
Study 8471652 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% BCAA solution
Number of subjects: 35
Study 8471652 — intervention group
Group type: COMPARATOR
Intervention: Standard AA solution (control group)
Number of subjects: 35
Study 4066178 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual retraining
Number of subjects: 0
Study 4066178 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 0
Study 30227258 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD + aPDT
Number of subjects: 72
Study 30227258 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD + CLM
Number of subjects: 72
Study 30227258 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD + CLM + aPDT
Number of subjects: 72
Study 30227258 — intervention group
Group type: COMPARATOR
Intervention: UPD
Number of subjects: 72
Study 30227258 — intervention group
Group type: COMPARATOR
Intervention: UPD + PDT
Number of subjects: 72
Study 26458517 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfering force field B (treatment group)
Number of subjects: 24
Study 26458517 — intervention group
Group type: COMPARATOR
Intervention: Force field A (control group)
Number of subjects: 24
Study 26458517 — intervention group
Group type: COMPARATOR
Intervention: Electroencephalography (EEG) measurements (control group)
Number of subjects: 24
Study 26458517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG) measurements (treatment group)
Number of subjects: 24
Study 24612288 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic resistance exercise at 60% MVC against right lateral jaw movements
Number of subjects: 12
Study 24612288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 21349603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Education (DE) and Physical Exercise (PE)
Number of subjects: 108
Study 21349603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 108
Study 21349603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Education (DE)
Number of subjects: 108
Study 21349603 — intervention group
Group type: COMPARATOR
Intervention: Individual consultations (Control group)
Number of subjects: 108
Study 19323612 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 957
Study 19323612 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 957
Study 17869298 — intervention group
Group type: EXPERIMENTAL
Intervention: InterStim implantation
Number of subjects: 163
Study 15547180 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-FAC
Number of subjects: 524
Study 15547180 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 524
Study 11674909 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Annotated Reminder Tool (CART)
Number of subjects: 0
Study 11674909 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11674909 — intervention group
Group type: EXPERIMENTAL
Intervention: CART
Number of subjects: 0
Study 9040722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.25 to 4 mg/d)
Number of subjects: 208
Study 9040722 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (100 to 600 mg/d)
Number of subjects: 208
Study 9040722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline with additional levodopa/carbidopa
Number of subjects: 208
Study 9040722 — intervention group
Group type: COMPARATOR
Intervention: Levodopa with additional levodopa/carbidopa
Number of subjects: 208
Study 7955181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (8 g/d of omega-3 fatty acids, 10 capsules of 1.0 g each containing 80.6% ethyl esters of omega-3 fatty acids, providing 4.1 g EPA and 2.8 g DHA)
Number of subjects: 551
Study 7955181 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (equal amount of ethyl ester of corn oil)
Number of subjects: 551
Study 2962799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5) 50 mg administered subcutaneously 3 times weekly for 1 month
Number of subjects: 49
Study 2962799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 760924 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour modification
Number of subjects: 81
Study 760924 — intervention group
Group type: COMPARATOR
Intervention: Absence of behaviour modification (Control)
Number of subjects: 81
Study 30587408 — intervention group
Group type: EXPERIMENTAL
Intervention: comfilcon A
Number of subjects: 0
Study 30587408 — intervention group
Group type: COMPARATOR
Intervention: lotrafilcon-B
Number of subjects: 0
Study 30587408 — intervention group
Group type: COMPARATOR
Intervention: samfilcon-A
Number of subjects: 0
Study 30587408 — intervention group
Group type: COMPARATOR
Intervention: filcom-V3
Number of subjects: 0
Study 27421817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg once daily
Number of subjects: 765
Study 27421817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 765
Study 27421817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 765
Study 25885172 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04937319 100 mg
Number of subjects: 639
Study 25885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 639
Study 25885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated glimepiride
Number of subjects: 639
Study 25885172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 24059475 — intervention group
Group type: EXPERIMENTAL
Intervention: State Mindfulness Scale (SMS) intervention
Number of subjects: 0
Study 24059475 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21346605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 30
Study 21346605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19379618 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC mesh packing
Number of subjects: 26
Study 19379618 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC gel packing
Number of subjects: 26
Study 19379618 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 26
Study 17581158 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus
Number of subjects: 22
Study 12845454 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoid artery ligation
Number of subjects: 60
Study 12845454 — intervention group
Group type: COMPARATOR
Intervention: Closed scissors hemorrhoidectomy
Number of subjects: 60
Study 11805451 — intervention group
Group type: COMPARATOR
Intervention: Topical heat application before exercise in normal controls
Number of subjects: 16
Study 11805451 — intervention group
Group type: COMPARATOR
Intervention: Topical heat application after exercise in normal controls
Number of subjects: 16
Study 11805451 — intervention group
Group type: COMPARATOR
Intervention: Ambient room temperature in subjects with myofascial pain
Number of subjects: 16
Study 11805451 — intervention group
Group type: COMPARATOR
Intervention: Topical heat application in subjects with myofascial pain
Number of subjects: 16
Study 10196552 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent displacement of visual target during saccadic eye movements
Number of subjects: 0
Study 10196552 — intervention group
Group type: COMPARATOR
Intervention: Random displacement of visual target during saccadic eye movements
Number of subjects: 0
Study 8156047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.250 mg/ml
Number of subjects: 53
Study 8156047 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.050 mg/ml
Number of subjects: 53
Study 8156047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 53
Study 8156047 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 53
Study 8156047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 53
Study 2963349 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapist management
Number of subjects: 107
Study 2963349 — intervention group
Group type: COMPARATOR
Intervention: Physician management
Number of subjects: 107
Study 31934793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) - two Iyengar yoga sessions a week
Number of subjects: 15
Study 31934793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) - three Iyengar yoga sessions a week
Number of subjects: 15
Study 31934793 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 15
Study 31934793 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with increased GABA levels at Scan-2
Number of subjects: 15
Study 31934793 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with no increase in GABA levels at Scan-2
Number of subjects: 15
Study 31322602 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard metal crowns (3M ESPE USA)
Number of subjects: 77
Study 31322602 — intervention group
Group type: COMPARATOR
Intervention: Filling materials (glass ionomer cements, compomers)
Number of subjects: 77
Study 28138765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide (0.01 µg/kg/min)
Number of subjects: 30
Study 28138765 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 30
Study 27012083 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedure (V basal osteotomy of the central metatarsals with elevation of the first metatarsal, dorsal osteotomy plus closing osteotomy, and elevation of the fifth metatarsal)
Number of subjects: 24
Study 23278590 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily for up to 6 weeks (1 cycle) followed by up to 4 weeks off therapy
Number of subjects: 65
Study 23278590 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily
Number of subjects: 65
Study 23278590 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag treatment
Number of subjects: 65
Study 22047926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl (1 mL of 50 μg)
Number of subjects: 60
Study 22047926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus tramadol (1 mL of 50 mg)
Number of subjects: 60
Study 22047926 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (30 mL of 0.25%)
Number of subjects: 60
Study 18461103 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting combined with plyometric exercises for 6 weeks
Number of subjects: 37
Study 18461103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 17154377 — intervention group
Group type: EXPERIMENTAL
Intervention: IV anti-D
Number of subjects: 9
Study 17154377 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 9
Study 15790189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day for 2 years)
Number of subjects: 20
Study 15790189 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg per day for 2 years)
Number of subjects: 20
Study 11708233 — intervention group
Group type: EXPERIMENTAL
Intervention: Responding in Peaceful and Positive Ways (RIPP) program
Number of subjects: 626
Study 11708233 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 9168368 — intervention group
Group type: COMPARATOR
Intervention: Hydration solution (5% dextrose)
Number of subjects: 258
Study 9168368 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PN (25% dextrose, 5% amino acids)
Number of subjects: 258
Study 7959860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 3301915 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine antiseptic (LA) 2 or 4 times daily for 2 weeks
Number of subjects: 103
Study 3301915 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC) twice daily for 2 weeks
Number of subjects: 103
Study 31719170 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichomonas vaginalis presence
Number of subjects: 647
Study 31719170 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichomoniasis
Number of subjects: 647
Study 31719170 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline trichomoniasis
Number of subjects: 647
Study 30015066 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg (potentially increasing to 50 mg) administered once weekly by subcutaneous injection
Number of subjects: 9463
Study 30015066 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo administered once weekly by subcutaneous injection
Number of subjects: 9463
Study 27196588 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 980
Study 27196588 — intervention group
Group type: COMPARATOR
Intervention: FS
Number of subjects: 980
Study 25771388 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid, 450‐1300 mg/day)
Number of subjects: 76
Study 25771388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (omega‐6 sunflower oil)
Number of subjects: 76
Study 23947319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis care coordination intervention including on-site screening, motivational-enhanced education and counseling, on-site vaccination, and case management services
Number of subjects: 489
Study 23947319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 489
Study 23947319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis care coordination intervention
Number of subjects: 489
Study 21060282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 37
Study 21060282 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/benserazide (L/B)
Number of subjects: 37
Study 21060282 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment (both PPX and L/B)
Number of subjects: 37
Study 18230236 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about a traumatic experience
Number of subjects: 104
Study 18230236 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing about best possible future selves (BPS)
Number of subjects: 104
Study 18230236 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing about a trivial topic
Number of subjects: 104
Study 17029688 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Location Learning Test (mLLT)
Number of subjects: 411
Study 14566216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 910
Study 14566216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study 11004817 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole once daily
Number of subjects: 97
Study 11004817 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole once daily
Number of subjects: 97
Study 11004817 — intervention group
Group type: COMPARATOR
Intervention: 20 mg famotidine twice daily
Number of subjects: 97
Study 8686198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (15.6 +/- 6.1 mg in one day morning dose)
Number of subjects: 20
Study 8686198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1306600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 100 mg ketoprofen with two placebo capsules
Number of subjects: 40
Study 1306600 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of placebo with two 50 mg ketoprofen capsules
Number of subjects: 40
Study 1306600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route of administration
Number of subjects: 40
Study 3930330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil
Number of subjects: 55
Study 3930330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31703293 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 min walk on a forest path
Number of subjects: 38
Study 31703293 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 min walk along a busy road
Number of subjects: 38
Study 31703293 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living
Number of subjects: 38
Study 29706089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation (CR)
Number of subjects: 90
Study 27562838 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo ward care (KWC)
Number of subjects: 141
Study 27562838 — intervention group
Group type: COMPARATOR
Intervention: Intermediate intensive care (IIC)
Number of subjects: 141
Study 27562838 — intervention group
Group type: EXPERIMENTAL
Intervention: KWC
Number of subjects: 141
Study 27562838 — intervention group
Group type: COMPARATOR
Intervention: IIC
Number of subjects: 141
Study 24534219 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/2w)
Number of subjects: 639
Study 24534219 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/w)
Number of subjects: 639
Study 24534219 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 639
Study 22309959 — intervention group
Group type: EXPERIMENTAL
Intervention: PG2
Number of subjects: 0
Study 22309959 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 0
Study 19875508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 60
Study 19875508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) propiverine (10, 15, 30 mg)
Number of subjects: 10
Study 18626633 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) propiverine (10, 15, 30, 45 mg)
Number of subjects: 10